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The Hazards of Comparative
Effectiveness When We
Cannot Effectively Compare*
Richard A. Lange, MD, L. David Hillis, MD
San Antonio, Texas
According to the Agency for Health Care Research and
Quality, “comparative effectiveness research is designed to
inform health-care decisions by providing evidence on the
effectiveness, benefits, and harms of different treatment
options” (1). The data derived from clinical registries play an
important role in assessing the effectiveness and appropri-
ateness of various treatments, and their use is likely to grow
in light of the increasing focus on assessing and improving
healthcare delivery and performing comparative effective-
ness studies. Such clinical registries capture data that reflect
“real-world” clinical practice in large patient populations (2).
See page 1020
Whereas most randomized controlled trials examine treat-
ment effects in highly selected patients who are enrolled and
studied at a limited number of sites and followed for a
relatively short time, observational clinical registries often
include data from larger numbers of patients with more
heterogeneous characteristics, many of whom are tradition-
ally underrepresented in randomized trials (i.e., women,
elderly, minorities, patients with various comorbid condi-
tions, and so on); these subjects often are gathered from a
large number of sites and are followed for a relatively long
duration. Although the data from observational clinical
registries are not designed to replace those that are obtained
from randomized controlled trials, they often offer insights
and information that are complementary to the results of
such randomized trials.
The major limitation of data obtained from observational
clinical registries is that differences in baseline characteris-
tics that are often present because the patients are not
assigned randomly to a particular treatment (i.e., known or
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relevant to the contents of this paper to disclose.unknown confounding factors) may affect the treatment
choice, leading to treatment selection bias. Accordingly,
several statistical tools, such as multivariate adjustments
based on regression analysis, stratification by background
characteristics, matching techniques, and propensity scor-
ing, are utilized in an attempt to “balance” these baseline
characteristics (e.g., biases) in the nonrandomized subjects.
Although the statistical methodologies that are employed in
an attempt to overcome these potential biases have become
more robust, they nonetheless continue to be limited by a
reliance on measured variables, which are typically tradi-
tional risk factors. In this issue of JACC: Cardiovascular
Interventions, McNulty et al. (3) draw attention to the
consequences of this limitation in assessing the comparative
effectiveness of percutaneous coronary intervention (PCI)
versus coronary artery bypass graft surgery (CABG) in
patients with unprotected left main (ULM) coronary artery
disease (CAD).
By carefully scrutinizing the records of 101 consecutive
patients with ULM CAD who underwent nonemergent
PCI at a California Kaiser Permanente Hospital, the inves-
tigators assessed how often these subjects were referred for
PCI because they were thought to be ineligible for CABG
and whether the conditions that made them ineligible for
CABG were identified by the American College of Cardi-
logy–National Cardiovascular Data Registry (ACC–NCDR)
ath-PCI Registry. This registry contains detailed informa-
ion on patient and hospital characteristics, coronary angio-
raphic findings, and PCI and in-hospital outcomes on 8
illion subjects from 1,000 sites within the United States
roughly 60% of American cardiac catheterization laborato-
ies); as such, it is the largest national registry of diagnostic
ardiac catheterization and PCI data and, as a result, is a
ommonly utilized source of data for comparative and appro-
riate use studies (4,5).
In the study of McNulty et al. (3), 54% of the patients
ndergoing nonemergent PCI for ULM CAD were
eemed to be ineligible for CABG. Not surprisingly, these
CABG-ineligible” patients had a greater prevalence of
raditionally measured risk factors and a higher estimated
ABG-associated mortality (using STS scores, NCDR
ath-PCI risk scores, and EuroScores) than those who were
hought to be eligible for CABG. Importantly, most of the
linical conditions cited as reasons for CABG ineligibility—
uch as active malignancy, frailty, dementia, severe aortic
alcification, or poor bypass targets or conduits—were not
aptured by the ACC–NCDR registry. One or more of these
onditions were present in 78% of the CABG-ineligible
atients and were independent predictors of mortality. After
djustment using the standard risk scores, patients with 1 or
ore of these “non–ACC–NCDR-captured” conditions were
to 6 times more likely to die during the 1.5 years of follow-up
hen compared with those without these conditions.
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1029What are the clinical implications of this study? Most
importantly, it highlights the potential problems of using
observational registry data (which may have been intended
for providing information regarding healthcare delivery
processes, quality, and outcomes) for “comparative effective-
ness” research. The unmeasured clinical conditions identi-
fied in the careful analysis of the 101 patients—as well as
others that may not have been identified in this study—
represent a substantial source of residual confounding for
studies comparing modes of revascularization that rely on
ACC–NCDR data for statistical adjustment of differences
in patient populations. A similar analysis of a much larger
population would likely reveal additional conditions that are
not currently being assessed, yet they contribute to the
treatment outcome. The study also points out that registry
data often provide limited insight into why treatments that
appear to be contrary to guidelines or appropriate use
criteria are selected.
The strengths of the study are the large number of
predictor variables analyzed by the investigators and the fact
that it was conducted at an integrated healthcare institution
(Kaiser), where decisions regarding the more appropriate
mode of coronary revascularization are not influenced by
economic incentives for physicians. The study has few
limitations. Although only patients with ULM CAD re-
ferred for nonemergent PCI were studied, it is likely that
similar treatment bias occurs in patients with multivessel
CAD without left main involvement (i.e., those with
malignancy, frailty, dementia, severe aortic calcification, or
poor bypass targets or conduits are referred for PCI rather
than CABG). Lastly, the determination and reason(s) for
CABG ineligibility were assessed retrospectively, not pro-
spectively. Nonetheless, the determination of “CABG inel-
igible” was based on the assessment of documentation by
the treating clinicians, not on an independent assessment of
eligibility for CABG by the chart reviewer.
How should the results of this study influence our current
practices? Standard definitions and criteria for diagnosing
“non–ACC–NCDR risk factors” (i.e., dementia, severe laortic calcification, end-stage liver disease, cachexia/frailty,
and so on) need to be established. These risk factors—and
those identified in the future—should be incorporated into
data collection and statistical models that “correct” for
baseline differences in patient populations (i.e., propensity
score analysis). When comparative effectiveness studies
utilize registry data, they should be scrutinized cautiously for
conditions that may potentially confound the findings.
Finally, the results of comparative effectiveness studies
derived from observational clinical registries should be
confirmed with additional registries that collect comple-
mentary data, when available. In short, basing healthcare
decisions on the results of comparative effectiveness studies
is hazardous when the treatment groups are not (or cannot
be) effectively compared.
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